OpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGNGet Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 2.5 %

Shares of OPGN opened at $0.61 on Monday. The business has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $0.51. The stock has a market cap of $7.74 million, a price-to-earnings ratio of -0.09 and a beta of -0.71. OpGen has a 52 week low of $0.17 and a 52 week high of $3.84.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.